Content overview

13th May 2026

The MHRA Orange Guide

This update contains changes regarding UK Guidance on Manufacture and UK Legislation on Manufacture and Importation.

13th May 2026

Herbal Medicines and Dietary Supplements

2 monographs have been selectively revised. Pharmacopoeial information has also been updated.

Selective revisions: Artichoke, Garlic.

Minor updates: The European Pharmacopoeia and USP-NF information have been globally updated.

13th May 2026

Drug Compatibility Checker

For May, published data have been added for 1 new drug and amended for 108 drugs from ASHP’s Injectable Drug Information. 7 new clinical practice reports from Palliative Care Formulary’s Syringe Driver Database have been added.

13th May 2026

Stockley’s Interactions Checker

For May, 250 new interactions have been added, and 1132 existing interactions have been updated.

13th May 2026

BNF for Children

This update contains 21 significant changes, 2 dose changes, 2 new monographs, and 1 deleted monograph.

Significant changes: 

• Adrenaline/epinephrine: name change to adrenaline.
• Albumin solution: name change to albumin.
• Anti-D (Rh0) immunoglobulin: name change to anti-D immunoglobulins.
• Antidiabetic drugs and drugs with neuromuscular blocking effects: pharmacodynamic effects drug groups deleted from Interactions.
• COVID-19 vaccines: updated guidance on the Spring 2026 immunisation campaign.
• Diphtheria with tetanus and pertussis vaccine: name change to diphtheria, tetanus, and pertussis vaccine.
• Diphtheria with tetanus and poliomyelitis vaccine: name change to diphtheria, tetanus, and poliomyelitis vaccine.
• Diphtheria with tetanus, pertussis and poliomyelitis vaccine: name
  change to diphtheria, tetanus, pertussis, and poliomyelitis vaccine.
• Diphtheria with tetanus, pertussis, poliomyelitis and haemophilus influenzae type b vaccine: name change to diphtheria, tetanus, pertussis, poliomyelitis, and haemophilus influenzae type b vaccine.
• Dried prothrombin complex: name change to prothrombin complex.
• Drugs with anticoagulant effects and drugs with antiplatelet effects: pharmacodynamic effects drug groups combined and renamed as drugs that cause bleeding; see Interactions.
• Haemophilus influenzae type b with meningococcal group C vaccine: name change to haemophilus influenzae type b and meningococcal group C vaccine.
• Influenza: updated guidance on management.
• Measles, mumps and rubella vaccine: name change to measles, mumps, and rubella vaccine.
• Meningococcal group B vaccine (rDNA, component, adsorbed): name change to meningococcal group B vaccine.
• Meningococcal groups A with C and W135 and Y vaccine: name change to meningococcal groups A, C, W135, and Y vaccine.
• Noradrenaline/norepinephrine: name change to noradrenaline.
• Pneumococcal polysaccharide conjugate vaccine (adsorbed): name change to pneumococcal polysaccharide conjugate vaccine.
• Respiratory syncytial virus (RSV) vaccine: name change to respiratory syncytial virus vaccine.
• Zanamivir: deleted indication and dose for treatment of influenza [uncomplicated, resistant to other treatments, and inhaled formulation unsuitable].
• Zanamivir: update to indications for prophylaxis and treatment of influenza.

Dose Changes:

• Baloxavir marboxil [update to age ranges and dosing for post-exposure prophylaxis of influenza and treatment of influenza].
• Oseltamivir [update to indication for post-exposure prophylaxis of influenza, and update to dosing for neonates in post-exposure prophylaxis of influenza].

New Monographs:

• Imvanex® [smallpox and mpox vaccines].
• Zavicefta® [ceftazidime with avibactam].

Deleted Monographs: Sotrovimab.

13th May 2026

British National Formulary

This update contains 29 significant changes, 3 dose changes, 2 new monographs, 2 new preparations, and 1 deleted monograph.

Significant Changes:

• Adrenaline/epinephrine: name change to adrenaline.
• Albumin solution: name change to albumin.
• Anti-D (Rh0) immunoglobulin: name change to anti-D immunoglobulins.
• Antidiabetic drugs and drugs with neuromuscular blocking effects: pharmacodynamic effects, drug groups deleted from Interactions.
• Cannabis extract: name change to cannabidiol with dronabinol.
• Ceftazidime with avibactam: new indication and dose for bacteraemia.
• Ceftazidime with avibactam: update to indication for Gram-negative infections.
• COVID-19 vaccines: updated guidance on the Spring 2026 immunisation campaign.
• Cyclogest® pessaries [progesterone]: new indication and dose for prevention of preterm birth.
• Diphtheria with tetanus and pertussis vaccine: name change to diphtheria, tetanus, and pertussis vaccine.
• Diphtheria with tetanus and poliomyelitis vaccine: name change to diphtheria, tetanus, and poliomyelitis vaccine.
• Diphtheria with tetanus, pertussis, and poliomyelitis vaccine: name change to diphtheria, tetanus, pertussis, and poliomyelitis vaccine.
• Diphtheria with tetanus, pertussis, poliomyelitis, and haemophilus influenzae type b vaccine: name change to diphtheria, tetanus, pertussis, poliomyelitis, and haemophilus influenzae type b vaccine.
• Dried prothrombin complex: name change to prothrombin complex.
• Drugs with anticoagulant effects and drugs with antiplatelet effects: pharmacodynamic effects drug groups combined and renamed as drugs that cause bleeding; see Interactions.
• Dutasteride: update to monitoring requirements and effect on laboratory tests.
• Finasteride: new monitoring requirements and update to effect on laboratory tests.
• Haemophilus influenzae type b with meningococcal group C vaccine: name change to haemophilus influenzae type b and meningococcal group C vaccine.
• Influenza: updated guidance on management.
• Measles, mumps and rubella vaccine: name change to measles, mumps, and rubella vaccine.
• Meningococcal group B vaccine (rDNA, component, adsorbed): name change to meningococcal group B vaccine.
• Meningococcal groups A with C and W135 and Y vaccine: name change to meningococcal groups A, C, W135, and Y vaccine.
• Molnupiravir: update to indication for COVID-19.
• Noradrenaline/norepinephrine: name change to noradrenaline.
• Obinutuzumab: new indication and dose for lupus nephritis.
• Pneumococcal polysaccharide conjugate vaccine (adsorbed): name change to pneumococcal polysaccharide conjugate vaccine.
• Respiratory syncytial virus (RSV) vaccine: name change to respiratory syncytial virus vaccine.
• Zanamivir: deleted indication and dose for treatment of influenza [uncomplicated, resistant to other treatments, and inhaled formulation unsuitable].

Dose Changes:

• Baloxavir marboxil [update to age ranges and dosing for post-exposure prophylaxis of influenza and treatment of influenza].
• Oseltamivir [update to indication for post-exposure prophylaxis of influenza, and renal dosing in adults].
• Utrogestan® vaginal capsules (progesterone) [update to dosing for supplementation of luteal phase during assisted reproductive technology (ART) cycles].

New Monographs: 

• Imvanex® [smallpox and mpox vaccines].
• Itovebi® [inavolisib].

New Preparations: Misabri® [pregabalin]; Prometrium® [progesterone].

Deleted Monographs: Sotrovimab